TBPMF - Tetra Bio-Pharma ships paid med to the U.S. for mid-stage trial

Tetra Bio-Pharma (TBPMF) announced that it has shipped the investigational therapy Qixleef to the U.S. for the initiation of a Phase 2 proof-of-concept trial in the management of breakthrough cancer pain (BTcP).After completing the production of Qixleef, the company has also obtained the cannabis export permit from Health Canada.A botanical drug with a "fixed ratio" of THC and CBD, Qixleef is inhaled through a vaporizer.REBORN1 is a 10-week open-label randomized study designed to evaluate the effect of Qixleef in comparison to morphine sulfate immediate release ("MSIR") in the pain relief of BTcP.Noting its commitment to fight the opioid crisis, CEO of the company Guy Chamberland said: “Tetra has worked hard to prepare QIXLEEF for clinical testing.”In January, Tetra Bio-Pharma announced that it received the FDA clearance for the study.

For further details see:

Tetra Bio-Pharma ships paid med to the U.S. for mid-stage trial